SCHEDULE: Armistice Capital Discloses 6% Stake in Alto Neuroscience
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have disclosed a 6% beneficial ownership stake in Alto Neuroscience, Inc., holding 1,624,000 shares of common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,624,000 shares of Alto Neuroscience, Inc. common stock.
- This represents 6% of the company's outstanding common stock.
- The percentage is based on 27,072,129 shares outstanding as of May 9, 2025, as reported in Alto Neuroscience's Form 10-Q filed on May 14, 2025.
- Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. The filing is a routine disclosure of beneficial ownership. The presence of a significant institutional investor (6%) can be seen as a positive signal of confidence in the company, but it does not provide new operational or financial performance data.
Positives
- Armistice Capital, LLC and Steven Boyd, as institutional investors, have taken a significant 6% stake in Alto Neuroscience, Inc., which may signal confidence in the company's prospects.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in a neuroscience company, which aligns with broader trends of investment in the biotechnology and pharmaceutical sectors, particularly in areas with high unmet medical needs.
Related Party Transactions
- Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, is an investment advisory client of Armistice Capital, LLC and is the direct holder of the shares. The Master Fund has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.
- Company Management: Awareness of a significant institutional holder may influence strategic decisions, though the filing states the stake is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 2025-05-09 | Date as of which 27,072,129 shares outstanding were reported in Alto Neuroscience's Form 10-Q. |
| 2025-05-14 | Date Alto Neuroscience's Form 10-Q was filed with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement (beneficial ownership reporting date). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Alto Neuroscience, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Neuroscience
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.